EV-Pembro Beats Chemo in Muscle- Invasive Bladder Cancer
Perioperative enfortumab vedotin plus pembrolizumab significantly improved survival compared with cisplatin-based chemotherapy in muscle-invasive bladder cancer.
ONC
The Latest on ONC
Overdue Last read · last published · next check
Last read 7 hours ago, longer than this feed's 1 hour schedule.
Latest posts
Is It Time for a New Type of Cancer Physician?
The dramatic increase in cancer survivorship is introducing questions about the ability of physicians to meet patient needs. Is it time to create a specialty for “survivorship physicians?”
Sonali M. Smith, MD
Sonali M. Smith, MD, is the Elwood V. Jensen Professorship of Medicine and the chief, section of hematology/oncology at UChicago Medicine.
Em Shone, BSN, RN, OCN
Em Shone, BSN, RN, OCN, is an oncology nurse located in Houston, Texas.
Shervin Tabrizi, MD
Shervin Tabrizi, MD, is an assistant professor of radiation oncology at the Perelman School of Medicine in Philadelphia, Pennsylvania.
Miriam Adina Knoll, MD
Miriam A. Knoll, MD, is a clinical assistant professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra University/Northwell Health in Glen Oaks, New York.
Combo Shows Survival Benefits in Advanced Breast Cancer
Giredestrant plus everolimus improved progression-free survival after subsequent therapy and chemotherapy-free survival in ER-positive, HER2-negative advanced breast cancer.
News Scan
A quick review of oncology headlines that matter most.
Challenging Clinical Case: A Pickleballer With CLL
A 71-year-old retired engineer who regularly plays pickleball is preparing to undergo treatment for his CLL. How much do you know about treatment options and pivotal trials that inform care?
Oncology News Central
Oncology News Central
New Book Provides “Window to the Entirety of Oncology”
The past and future of CLL care are presented as “a window to the entirety of oncology” in *Ghosts in the Blood*, set for release this September.
Community Oncology Alliance
Serving as the voice of community oncology in Washington, DC, and across the country, the Community Oncology Alliance (COA) aims to improve patient care, offer professional growth for cancer care providers, and support practice operations. Individuals from every level of the cancer care delivery team, including oncologists, hematologists, pharmacists, oncology nurses and nurse practitioners,…
Meet Community Oncology’s “Energizer Bunny”
Harsha Vyas, MD, founded rural Georgia’s only physician-owned oncology practice 14 years ago. Here’s how he has kept cancer care flourishing where it didn’t before.
FDA Approves Multiple Myeloma Combo Regimen
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase-fihj and dexamethasone for adults with relapsed multiple myeloma.
Jeff Sharman, MD
Jeff Sharman, MD, is the director of research at the Willamette Valley Cancer Institute as well as the medical director of hematology research for The US Oncology Network.
New Therapies Reshape ALK- and ROS1-Mutated NSCLC Care
Sandip P. Patel, MD, shares which recent developments could affect clinical practice in ROS1- and ALK-positive non-small cell lung cancer.
Will FDA Follow EU in Approving Breast Cancer Drug?
The European Union’s recent approval of camizestrant using the SERENA-6 switch strategy could strengthen the drug’s case with regulators in the United States.